Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 4/20 | 0.42 |
| ▸ | FABP3 | P05413 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30587182 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2KMT2AMEN1GAALMNA | |
| SCHEMBL8439147 | 0.91 | FABP3 (0.48) | SMN1; SMN2KMT2AGAALMNATSHR | |
| SCHEMBL6509414 | 0.90 | LMNA (0.58) | SMN1; SMN2KMT2AMEN1GAALMNA | |
| SCHEMBL13410042 | 0.88 | GAA (0.47) | SMN1; SMN2KMT2AMEN1GAALMNA | |
| SCHEMBL6949718 | 0.88 | GAA (0.56) | SMN1; SMN2KMT2AMEN1GAALMNA | |
| SCHEMBL30686655 | 0.88 | GAA (0.56) | SMN1; SMN2KMT2AMEN1GAALMNA | |
| SCHEMBL31231118 | 0.88 | GAA (0.56) | SMN1; SMN2KMT2AMEN1GAALMNA | |
| SCHEMBL28402122 | 0.84 | LMNA (0.50) | SMN1; SMN2KMT2AMEN1GAALMNA | |
| SCHEMBL10747419 | 0.84 | GAA (0.44) | SMN1; SMN2GAALMNAHTTTSHR | |
| SCHEMBL18680220 | 0.84 | KMT2A (0.47) | KMT2ATSHRKDM4EALDH1A1FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107449834-B | Method for detecting clevidipine and related substances in fat emulsion injection thereof | 江苏正大丰海制药有限公司 | 2020-04-07 | — | — | CN | claimed |
| EP-1023267-B1 | PYRIDYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CERMOL SA (CH) | 2003-09-17 | — | — | EP | claimed |
| US-11737989-B2 | Clevidipine nanoparticles and pharmaceutical compositions thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-08-29 | — | — | US | disclosed |
| US-20230145206-A1 | CLEVIDIPINE NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | CHIESI FARM SPA (IT) | 2023-05-11 | — | — | US | disclosed |
| CN-107449834-B | Method for detecting clevidipine and related substances in fat emulsion injection thereof | 江苏正大丰海制药有限公司 | 2020-04-07 | — | — | CN | disclosed |
| US-20170087093-A1 | Clevidipine Nanoparticles and Pharmaceutical Compositions Thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-03-30 | — | — | US | disclosed |
| EP-3145508-A1 | CLEVIDIPINE NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | The Medicines Company (US) | 2017-03-29 | — | — | EP | disclosed |
| WO-2015179334-A1 | CLEVIDIPINE NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE MEDICINES COMPANY (US) | 2015-11-26 | — | — | WO | disclosed |
| EP-1133473-A1 | NEW MANUFACTURING PROCESS | AstraZeneca AB (SE) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000031035-A1 | NEW MANUFACTURING PROCESS | ASTRAZENECA AB (SE) | 2000-06-02 | — | — | WO | disclosed |
| EP-0127150-A2 | 2,6-Disubstituted-1,4-dihydropyridine derivative, process for the preparation of the same and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145206-A1 | CLEVIDIPINE NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | DLST, CLSPN, CSPP1 | SMN1; SMN2 574/4885KMT2A 2899/4885MEN1 1306/4885 |
| US-11737989-B2 | Clevidipine nanoparticles and pharmaceutical compositions thereof | DLST, CLSPN, CSPP1 | SMN1; SMN2 574/4885KMT2A 2899/4885MEN1 1306/4885 |
| US-20170087093-A1 | Clevidipine Nanoparticles and Pharmaceutical Compositions Thereof | DLST, CLSPN, CSPP1 | SMN1; SMN2 574/4885KMT2A 2899/4885MEN1 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.